Endovascular recanalization of basilar artery occlusion 80 days after symptom onset.
OBJECTIVE
Acute basilar artery occlusion portends high risk of stroke and death. Thrombolysis or endovascular therapy has been limited to patients who present within hours of symptom onset. Without recanalization, acute basilar artery occlusion almost always results in death or severe disability.


METHODS
We report a case of basilar artery occlusion and successful endovascular recanalization 80 days after symptom onset.


CONCLUSIONS
Endovascular therapy can be feasible and safe for symptomatic basilar artery occlusion at chronic stage.
Yu
Wengui
W
Department of Neurology, University of California, Irvine, CA, USA. wyu@yahoo.com
Kostanian
Varoujan
V
Fisher
Mark
M
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001488:Basilar Artery / Q000187:drug effects* / Q000503:physiopathology / Q000601:surgery*; D002533:Cerebral Angiography; D002908:Chronic Disease; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006261:Headache / Q000209:etiology; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010291:Paresis / Q000209:etiology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D015607:Stents / Q000592:standards*; D015912:Thrombolytic Therapy / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014656:Vascular Surgical Procedures / Q000295:instrumentation / Q000379:methods*; D014715:Vertebrobasilar Insufficiency / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D015354:Vision, Low / Q000209:etiology
D000911:Antibodies, Monoclonal; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D010959:Tissue Plasminogen Activator; D000077284:Abciximab